только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 22 / 26
Страница 1 / 1

Рекомендуемая литература.

  1. Raghu G, Collard HR, Egan JJand ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis; evidence-based guidelines for diag- nosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
  2. Raghu G, Rochwerg B, Zhang Y, Cuello Garcia CA, Azuma A, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: Executive Summary An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192: e3–e19.
  3. Travis WD, Costabe U, Hansell DM, and ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748.
  4. Ryu JH, Moua T, Daniels CE, et al. Idiopathic pulmonary fibrosis: Evolving concepts. Mayo Clin Proc 2014; 89: 1130-42.
  5. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease. Proc Am Thorac Soc. 2006; 3: 293–8.
  6. El-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology 1997; 113: 755–60.
  7. Lee J.S., Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012; 39: 352–8.
  8. Garcıa-Sancho Figueroa MC, Carrillo G, Perez-Padilla R, et al. Risk factors for idiopathic pulmonary fi- brosis in a Mexican population. A case–control study. Respir Med 2010; 104: 305–9.
  9. Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 2014; 9: 157-79.
  10. Hodgson U, Pulkkinen V, Dixon M, et al. ELMOD2 is a candidate gene for familial idiopathic pulmo- nary fibrosis. Am J Hum Genet 2006; 79: 149–154.
  11. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pul- monary fibrosis. Am J Respir Crit Care Med 2006; 174: 810–816.
  12. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967–972.
  13. Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012; 21: 355–361.
  14. Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Medicine 2015; 13: 237.
  15. Johnston IDA, Prescott RJ, Chalmers JC, et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 1997; 52: 38-44.
  16. du Bois RM, Wells AU. Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur Respir J 2001; 18: Suppl. 32, 43s–55s.
  17. Piirila P, Sovijarvi ARA. Crackles: recording, analysis and clinical significance. Eur Respir J 1995; 8: 2139- 2148.
  18. Flaherty KR, King TE Jr, Raghu G, Lynch JP III, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, et al. Idiopathic interstitial pneumonia: what is the effect of a ultidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004;170:904–910.
  19. Monaghan H, Wells AU, Colby TV, du Bois RM, Hansell DM, Nicholson AG. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 2004; 125: 522–526.
  20. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001; 164: 1722–1727.
  21. Miller JD, Urschel JD, Cox G, Olak J, Young JE, Kay JM, McDonald E. A randomized, controlled trial comparing thoracoscopy and limited thoracotomy for lung biopsy in interstitial lung disease. Ann Thorac Surg 2000; 70: 1647–1650.
  22. Carnochan FM, Walker WS, Cameron EW. Efficacy of video assisted thoracoscopic lung biopsy: an his- torical comparison with open lung biopsy. Thorax 1994; 49: 361–363.
  23. Leslie KO, Gruden JF, Parish JM, Scholand MB. Transbronchial biopsy interpretation in the patient with diffuse parenchymal lung disease. Arch Pathol Lab Med 2007; 131: 407–423.
  24. Grenier P, Valeyre D, Cluzel P, Brauner MW, Lenoir S, Chastang C. Chronic diffuse interstitial lung disease: diagnostic value of chest radiography and high-resolution CT. Radiology 1991; 179: 123-132
  25. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imag- ing. Radiology 2008; 246: 697–722.
  26. Johkoh T, Sakai F, Noma S, et al. Honeycombing on CT: its definitions, pathologic correlation, and fu- ture directionof its diagnosis. Eur J Radiol 2014; 83: 27–31.
  27. Sverzellati N, Wells AU, Tomassetti S, et al. Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses. Radiology 2010; 254: 957–964.
  28. Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, Andreas S, Claussen M, Grohé C, Wilkens H, Randerath W, Skowasch D, Meyer FJ, Kirschner J, Gläser S, Herth FJ, Welte T, Huber RM, Neu- rohr C, Schwaiblmair M, Kohlhäufl M, Höffken G, Held M, Koch A, Bahmer T, Pittrow D. Management of pa- tients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J 2015; 46: 186-196.
  29. Wiggins J, Strickland B, Turner-Warwick M. - Combined cryptogenic fibrosing alveolitis and emphy- sema: the value of high resolution computed tomography in assessment. Respir.Med. 1990. 84: 365-369.
  30. Doherty MJ, Pearson MG, O’Grady EA, et al. Cryptogenic fibrosing alveolitis with preserved lung vol- umes. Thorax. 1997. 52: 998-1002.
  31. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
  32. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU. Forced vital capacity in patients with idiopathic pul- monary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
  33. Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr. Validation of test performance characteristics and minimal clinically im- portant difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med 2015; 109: 914-922.
  34. Nicholson A.G. Interstitial pneumonias. In: Dail and Hammar's Pulmonary Pathology. Third Edition. /Ed. Philip T. Cagle, Armando E. Fraire, Joseph F. Tomashefski, Jr., Carol F. Farver. Springer Sci- ence+Business Media, LLC. 2008: 695-721.
  35. Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med 2008; 19: 227–235.
  36. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517–525.
  37. King TE, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring sys- tem and survival model. Am J Respir Crit Care Med 2001; 164: 1171–1181.
  38. Kim D.S., Collard H.R., King T.E. Classification and natural history of the idiopathic interstitial pneu- monias. Proc Am Thorac Soc 2006; 3: 285-92.
  39. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, et al. Acute exacerbations of idiopathic pul- monary fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016; 194: 265–275.
  40. Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 1997; 168: 79– 83.
  41. Ambrosini V, Cancellieri A, Chilosi M, Zompatori M, Trisolini R, Saragoni L, Poletti V. Acute exacer- bation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003; 22: 821–826.
  42. Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, Bisceglia M, Gilbert S, Yousem SA, Song JW, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 180: 167–175.
  43. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmo- nary fibrosis: frequency and clinical features. Eur Respir J 2006; 27: 143–150.
  44. Kondoh Y, Taniguchi H, Kitaichi M, Yokoi T, Johkoh T, Oishi T, Kimura T, Nishiyama O, Kato K, du Bois RM. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med 2006; 100: 1753–1759.
  45. Hiwatari N, Shimura S, Takishima T, Shirato K. Bronchoalveolar lavage as a possible cause of acute ex- acerbation in idiopathic pulmonary fibrosis patients. Tohoku J Exp Med 1994; 174: 379–386.
  46. Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerba- tion of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005; 128: 3310–3315.
  47. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, Israel-Biet D, Court- Fortune I, Valeyre D, Cordier JF; Groupe d’Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26: 586–593.
  48. Stahel RA, Gilks WR, Lehmann HP, Schenker T. Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int J Cancer Suppl 1994; 8: 6–26.
  49. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of in- terstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest 1989; 96: 68–73.
  50. Авдеева О.Е., Лебедин Ю.С., Авдеев С.Н., Чуканов С., Черняк А.В., Самсонова М.В., Чучалин А.Г. Гликозилированный муцин-антиген 3EG5 − сывороточный маркер активности и тяжести при интерстициальных заболеваниях легких. Пульмонология 1998; №2: 22-27.
  51. Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, Nagae H, Ma- son RJ. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002; 19: 439–446.
  52. Shinoda H, Tasaka S, Fujishima S, Yamasawa W, Miyamoto K, Nakano Y, Kamata H, Hasegawa N, Ishizaka A. Elevated CC chemokine level in bronchoalveolar lavage fluid is predictive of a poor outcome of idiopathic pulmonary fibrosis. Respiration 2009; 78: 285–292.
  53. Leuchte HH, Baumgartner RA, Nounou ME, Vogeser M, Neurohr C, Trautnitz M, Behr J. Brain natriu- retic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173: 744–750.
  54. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdon- ald SD, Pardo A, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fi- brosis. PLoS Med 2008; 5: e93.
  55. Phelps DS, Umstead TM, Mejia M, Carrillo G, Pardo A, Selman M. Increased surfactant protein-A lev- els in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest 2004; 125: 617–625.
  56. McCormack FX, King TE Jr, Bucher BL, Nielsen L, Mason RJ. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 152: 751–759.
  57. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 588–594.
  58. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; (3): CD003134.
  59. Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; (3): CD002880.
  60. Gay SE, Kazerooni EA, Toews GB, Lynch JP III, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157: 1063–1072.
  61. Flaherty KR, Toews GB, Lynch JP III, Kazerooni EA, Gross BH, Strawderman RL, Hariharan K, Flint A, Martinez FJ. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, re- sponse to therapy, and survival. Am J Med 2001; 110: 278–282.
  62. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353 2229–2242.
  63. Oldham JM, Ma S-F, Martinez FJ, et al. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2015; 192: 1475–1482.
  64. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ; Idiopathic Pulmonary Fibrosis Clinical Re- search Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968–1977.
  65. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, No- ble PW, Raghu G, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079–1087.
  66. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
  67. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth fac- tors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008; 590: 400–408.
  68. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hop- kins PM, Kardatzke D, Lancaster L, et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
  69. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000; 161: 1172–1178.
  70. Morrison DA, Stovall JR. Increased exercise capacity in hypoxemic patients after long-term oxygen therapy. Chest 1992; 102: 542–550.
  71. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391–398.
  72. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchi- tis and emphysema: report of the Medical Research Council Working Party. Lancet 1981; 1: 681–686.
  73. Mason DP, Brizzio ME, Alster JM, McNeill AM, Murthy SC, Budev MM, Mehta AC, Minai OA, Pet- tersson GB, Blackstone EH. Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg 2007; 84: 1121–1128.
  74. Keating D, Levvey B, Kotsimbos T, Whitford H, Westall G, Williams T, Snell G. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc 2009; 41: 289–291.
  75. Thabut G, Mal H, Castier Y, Groussard O, Brugiere O, Marrash-Chahla R, Leseche G, Fournier M. Sur- vival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003; 126: 469–475.
  76. Egan JJ, Martinez FJ, Wells AU, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005; 60: 270–273.
  77. Thabut G, Christie JD, Ravaud P, Castier Y, Dauriat G, Jebrak G, Fournier M, Leseche G, Porcher R, Mal H. Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann Intern Med 2009; 151: 767–774.
  78. Stern JB, Mal H, Groussard O, Brugiere O, Marceau A, Jebrak G, Fournier M. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest 2001; 120: 213–219.
  79. Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerba- tion of idiopathic pulmonary fibrosis. Can Respir J 2004; 11: 117–122.
  80. Mollica C, Paone G, Conti V, Ceccarelli D, Schmid G, Mattia P, Perrone N, Petroianni A, Sebastiani A, Cecchini L, et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration 2010; 79: 209–215.
  81. Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med 2008; 102: 1355–1359.
  82. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63: 549–554.
  83. Nishiyama O, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S, Nishimura K, Taniguchi H. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008; 13: 394–399.
  84. Ferreira A, Garvey C, Connors GL, Hilling L, Rigler J, Farrell S, Cayou C, Shariat C, Collard HR. Pul- monary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009; 135: 442–447.
  85. Jastrzebski D, Gumola A, Gawlik R, Kozielski J. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J Physiol Pharmacol 2006; 57: 139–148.
  86. Naji NA, Connor MC, Donnelly SC, McDonnell TJ. Effectiveness of pulmonary rehabilitation in restric- tive lung disease. J Cardiopulm Rehabil 2006; 26: 237–243.
  87. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895–900.
  88. Madden BP, Allenby M, Loke T, Sheth A. A potential role for sildenafil in the management of pulmo- nary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006; 44: 372–376.
  89. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131: 897–899.
  90. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, Seeger W. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160: 600–607.
  91. Minai OA, Sahoo D, Chapman JT, Mehta AC. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir Med 2008; 102: 1015–1020.
  92. Raghu G., Yang S.T., Spada C., et al. Sole treatment of acid gastroesophageal reflux in idiopathic pul- monary fibrosis: a case series. Chest 2006; 129: 794-800.
  93. Linden P.A., Gilbert R.J., Yeap B.Y., et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006; 131: 438-446.
  94. Lee J.S., Ryu J.H., Elicker B.M., et al. Gastroesophageal reflux therapy is associated with longer surviv- al in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:1390-4.
  95. Savarino E., Bazzica M., Zentilin P., et al. Gastroesophageal reflux and pulmonary fibrosis in sclero- derma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009; 179: 408-413.
  96. Gulmez S.E., Holm A., Frederiksen H., et al. Use of proton pump inhibitors and the risk of community- acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950-955.
  97. Yang Y.X., Lewis J.D., Epstein S., et al: Long-term proton pump inhibitor therapy and risk of hip frac- ture. JAMA 2006; 296: 2947-2953.
  98. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538–542.
  99. King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171– 177.
  100. Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, Hansell DM, du Bois RM, Wells AU. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830–836.
  101. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr, Idiopathic Pulmo- nary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pul- monary fibrosis. N Engl J Med 2004; 350: 125–133.
  102. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040–1047.
  103. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS state- ment: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111–117.

Для продолжения работы требуется вход / регистрация